U-BIOPRED is a research project created under the European Commission’s 7th Framework Innovative Medicines Initiative (IMI) to increase understanding of severe asthma through analysis and systems biology. The project consortium includes collaboration from universities, research institutes and the pharmaceutical industry, as well as small and medium enterprises (SMEs) who cooperate to accelerate the discovery of improved treatments for patients. The project specifically addresses knowledge gaps for severe asthma and seeks to identify potential new treatments, along with the best ways to make such treatments available to the general public. Within the project itself, EFA is a partner aiding with communication, dissemination of information, answering ethical questions and providing patient perspective. EFA participates in the annual general meeting for U-BIOPRED partners and participates monthly in work packages (WPs) 9 and 10, which specifically concern dissemination and ethics respectively.
U-BIOPRED
Unbiased BIOmarkers in PREDiction of respiratory disease outcomes (U-BIOPRED)
U-BIOPRED is a research project created under the European Commission’s 7th Framework Innovative Medicines Initiative (IMI) to increase understanding of severe asthma through analysis and systems biology. The project consortium includes collaboration from universities, research institutes and the pharmaceutical industry, as well as small and medium enterprises (SMEs) who cooperate to accelerate the discovery of improved treatments for patients. The project specifically addresses knowledge gaps for severe asthma and seeks to identify potential new treatments, along with the best ways to make such treatments available to the general public. Within the project itself, EFA is a partner aiding with communication, dissemination of information, answering ethical questions and providing patient perspective. EFA participates in the annual general meeting for U-BIOPRED partners and participates monthly in work packages (WPs) 9 and 10, which specifically concern dissemination and ethics respectively.
U-BIOPRED is a research project created under the European Commission’s 7th Framework Innovative Medicines Initiative (IMI) to increase understanding of severe asthma through analysis and systems biology. The project consortium includes collaboration from universities, research institutes and the pharmaceutical industry, as well as small and medium enterprises (SMEs) who cooperate to accelerate the discovery of improved treatments for patients. The project specifically addresses knowledge gaps for severe asthma and seeks to identify potential new treatments, along with the best ways to make such treatments available to the general public. Within the project itself, EFA is a partner aiding with communication, dissemination of information, answering ethical questions and providing patient perspective. EFA participates in the annual general meeting for U-BIOPRED partners and participates monthly in work packages (WPs) 9 and 10, which specifically concern dissemination and ethics respectively.